Holen Sie sich die Stockscreener-App
1.62
3.85%
0.06
Handel nachbörslich:
1.62
Schlusskurs vom Vortag:
$1.56
Offen:
$1.55
24-Stunden-Volumen:
1.04M
Relative Volume:
0.89
Marktkapitalisierung:
$458.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-1.9756
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
+13.29%
1M Leistung:
+11.72%
6M Leistung:
-0.61%
1J Leistung:
-37.69%
1-Tages-Spanne:
$1.53
$1.705
1-Wochen-Bereich:
$1.38
$1.705
52-Wochen-Spanne:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.62 | 419.27M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-26 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Risk adjusted return profile for Erasca Inc. analyzedDip Buying & Stepwise Trade Signal Implementation - Newser
Predicting Erasca Inc. trend using moving averagesWeekly Profit Analysis & Verified Swing Trading Watchlists - Newser
Technical analysis overview for Erasca Inc. stock2025 Volume Leaders & Daily Risk Controlled Trade Plans - Newser
Is Erasca Inc. stock entering bullish territoryJuly 2025 Action & Pattern Based Trade Signal System - Newser
Market reaction to Erasca Inc.’s recent newsEarnings Recap Summary & Weekly Top Gainers Trade List - Newser
Published on: 2025-08-13 05:24:19 - Newser
Erasca Reports Progress and Financial Stability in Q2 2025 - TipRanks
Erasca Narrows Loss 46% in Fiscal Q2 - The Motley Fool
How to track smart money flows in Erasca Inc.Short-Term Support and Resistance Forecast - Newser
Erasca Q2 Loss Narrows, Cash Runway Good Until H2 2028 - MarketScreener
Earnings Flash: (ERAS) Erasca Q2 Loss $0.12 Vs FactSet Est. $0.12 Loss - MarketScreener
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cancer Drug Developer Erasca Secures 3-Year Runway as Two Key Therapies Enter Clinical Trials - Stock Titan
How Erasca Inc. stock performs during market volatilityEntry Confirmation Based on Volatility Analysis - Newser
Is it too late to sell Erasca Inc.Smart Entry Watchlist with Daily Analysis - Newser
Why Erasca Inc. stock is on top investor watchlistsVolatility Analysis and Entry Risk Mapping - Newser
Multi factor analysis applied to Erasca Inc.Fundamental + Technical Combined Watchlist - Newser
How moving averages guide Erasca Inc. tradingDaily Entry Opportunity Forecasting Tool - Newser
What technical models suggest about Erasca Inc.’s comebackFree Triple Return Setup with Risk Control - Newser
Erasca Inc. stock momentum explainedNeural Network Based Equity Prediction System - Newser
Should you wait for a breakout in Erasca Inc.Trade Ideas Based on Fundamental Metrics - Newser
When is the best time to exit Erasca Inc.Free AI Powered High Return Stock Calls - Newser
Using data tools to time your Erasca Inc. exitSwing Trade Planning with Consistent Setup - Newser
Erasca (ERAS) to Release Quarterly Earnings on Monday - Defense World
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) PT at $4.57 - Defense World
How to build a dashboard for Erasca Inc. stockFree Weekly Top Gainers Forecast Watchlist - Newser
Can Erasca Inc. Rally Enough to Break EvenWeekly Chart Analysis With Entry Advice Provided - metal.it
Heatmap Data Shows High Activity in Erasca Inc. SectorLow Risk Swing Trade Opportunities Identified - metal.it
Erasca discloses new GTPase KRAS mutant inhibitors - BioWorld MedTech
Fibonacci Levels Suggest Recovery for Erasca Inc.Consistent Gain Investment Strategies Emerge - beatles.ru
Why is Erasca Inc. stock attracting strong analyst attentionFree Predictions - Jammu Links News
What analysts say about Erasca Inc. stockFastest-growing stock picks - Jammu Links News
Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors - MSN
Is it the right time to buy Erasca Inc. stockTap into rapid wealth building techniques - Jammu Links News
Is Erasca Inc. stock overvalued or undervaluedCapitalize on proven investment strategies - Jammu Links News
What catalysts could drive Erasca Inc. stock higher in 2025Massive portfolio appreciation - Jammu Links News
Published on: 2025-08-04 01:33:01 - Jammu Links News
When is Erasca Inc. stock expected to show significant growthGet professional guidance for market timing - Jammu Links News
How does Erasca Inc. compare to its industry peersDiscover market opportunities with expert help - Jammu Links News
What makes Erasca Inc. stock price move sharplyAchieve rapid portfolio growth with expert guidance - Jammu Links News
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):